Joseph Lambing

Joe Lambing, Ph.D., has more than 20 years of drug development experience in the areas of cardiovascular disease, inflammation and oncology. During his career, Dr. Lambing has contributed to numerous NDA and IND filings for more than a dozen new chemical entities, as well as numerous filings to support a variety of clinical trials in other countries. Prior to joining MyoKardia, he was senior vice president of development for Portola Pharmaceuticals, where he oversaw all preclinical and pharmaceutical development activities since the company’s founding in 2003. Prior to Portola, Dr. Lambing served as director of drug safety and disposition for Millennium Pharmaceuticals’ San Francisco site, and director of DMPK and toxicology at COR Therapeutics.

Dr. Lambing holds a B.S. in chemistry and a Ph.D. in biochemistry from the University of Missouri, and was a postdoctoral fellow at the University of California, San Diego.